The role of antithyroglobulin, antiperoxidase and anti-TSH receptor autoantibodies in amiodarone-induced thyrotoxicosis and amiodarone-induced hypothyroidism (A two-center study)

Agata Czarnywojtek 1,2#, Barbara Czarnocka 3#, Małgorzata Zgorzalewicz-Stachowiak 4#, Kosma Woliński 2#, Marta Fichna 1, Maria Teresa Płazińska 5, Adam Stangierski 2, Paweł Gut 2, Izabela Miechowicz 6, Hanna Komarowska 2, Joanna Waligórska-Stachura 2, Ryszard Waśko 2, Marek Ruchała 2

1 Department of Pharmacology, Poznan University of Medical Sciences, ul Rokietnicka 5a, 60 806 Poznan, Poland
2 Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, 49 Przybyszewske Street, 60-355 Poznan, Poland
3 Department of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, ul. Marymoncka 99/103, 01-813 Warszawa, Poland
4 Laboratory of Medical Electrodiagnostics, Department of Health Prophylaxis, University of Medical Sciences in Poznan, Poland
5 Nuclear Medicine Department, Medical University of Warsaw, Warsaw, Poland
6 Department of Computer Science and Statistics, University of Medical Sciences in Poznan, Poland

# These authors contributed equally to this work

IN MEMORY OF PROFESSOR RYSZARD WAŚKO

Correspondence to: Agata Czarnywojtek
Department of Endocrinology, Metabolism and Internal Medicine
Poznan University of Medical Sciences
49 Przybyszewske Street, 60-355 Poznan, Poland.
E-mail: agata.rat@wp.pl

Submitted: 2015-11-17 Accepted: 2015-12-02 Published online: 2015-12-28

Key words: amiodarone; amiodarone-induced hyperthyroidism; amiodarone-induced hypothyroidism; thyroid auto-antibodies

OBJECTIVE: It has been reported that patients experiencing side effects of amiodarone (AM) therapy, such as amiodarone-induced thyrotoxicosis (AIT) or amiodarone-induced hypothyroidism (AIH), have changes in serum concentrations of anti-TSH receptor (TSHR), antithyroglobulin (Tg), and antiperoxidase (TPO) autoantibodies (Abs). The purpose of our study was to identify and analyze the changes in levels of listed antibodies in patients with several thyroid disorders.

METHODS: 280 patients from two centers in Poland were included. Titers of TSHR-Abs, TPO-Abs and Tg-Abs were analyzed retrospectively in the following groups of patients: A – euthyroid patients with a history of hyperthyroidism prior to re-administration of AM; B – patients with AIT who discontinued the AM therapy; C – patients with AIT chronically treated with AM; D – hypothyroid patients.

RESULTS: Serum Tg-Abs were not elevated in any of the studied groups. However, there were significant differences between A and B and also D and other groups (p<0.05). TPO-Abs titers were not elevated in most cases, there were no significant
differences between groups. The serum titers of TSHR-Abs were not elevated in any group. We found statistically significant differences between B and D, C and other groups (p<0.05).

**CONCLUSIONS:** Regardless of the statistically significant differences observed for Tg-Abs and TSHR-Abs levels, this observation has a limited clinical applicability. In almost all cases we observed normal to slightly increased titers of TPO-Abs, Tg-Abs, TSHR-Abs. Discontinuation or continuation of AM therapy had no influence on autoantibody titers. Furthermore, we found it impossible to differentiate between the type I and II of AIT based on autoantibody titers.

**Abbreviations:**

- AAD - antiarrhythmic drug
- AF - atrial fibrillation
- AIH - amiodarone-induced hypothyroidism
- AIT - amiodarone-induced thyrotoxicosis
- AM - amiodarone
- IFN-α - Interferon-α
- RAIU - radioiodine uptake
- Tg-Abs - thyroglobulin autoantibodies
- TH - thyroid hormones
- TPO-Abs - thyroperoxidase autoantibodies
- TSHR-Abs - autoantibodies to the thyrotropin receptor

**INTRODUCTION**

Amiodarone (AM) remains the most effective antiarrhythmic drug (AAD), particularly in the treatment of various chronic heart conditions (Singh et al. 1995, Mason et al. 1983). It is used in the primary prevention of atrial fibrillation (AF) or in the conversion of AF into sinus rhythm (Conolly 1999). AM is also used in treatment of ventricular tachyarrhythmias, especially in the prevention of sudden cardiac death (Reiffel et al. 1994). Unfortunately, AM therapy is associated with many side effects including severe toxicity of the lungs, liver, nerves, skin, and thyroid (Fogoros et al. 1983; Greene et al. 1983; Morady et al. 1983; Winkle et al. 1985; Czarnywojtek et al. 2013b).

The pathogenesis of the AM's effect on the thyroid is not entirely clear (Bartalena et al. 1996; Martino et al. 2001; Bogazzi et al. 2010). It may induce both hypothyroidism (AIH) and hyperthyroidism (AIT). In contrast to AIH, AIT constitutes great problem, even for experienced endocrinologists and nuclear medicine specialists. Due to amiodarone's long half-life it accumulates in tissues (Kurt et al. 2008; Han & Williams 2009). This means that hyperthyroidism may develop during AM therapy or many months after its withdrawal (Martino et al. 2001).

AIT is often classified into two different types. Type I AIT occurs in patients with underlying thyroid pathology like Graves’ disease. In these patients the addition of a large amount of iodine from AM therapy leads to accelerated thyroid hormone synthesis – this is known as the Jod-Basedow phenomenon. In contrast, type II AIT is due to the direct toxic effect of AM and its metabolite (benzofuran) and it leads to destructive inflammation of the thyroid. In these patients, subacute thyroiditis results in excess release of fT3 and fT4 and subsequent severe hyperthyroidism. Type II AIT develops in people with a normal thyroid, often in areas rich in iodine (Martino et al. 2001). Clinically, it is very difficult to separate the two types of AIT (Bartalena et al. 2002; Piga et al. 2008; Bogazzi et al. 2010). Beside radioiodine uptake (RAIU) (Martino et al. 2001), thyroid [99mTc]2-methoxy-isobutyl-isonitrile (MBI) scintigraphy (Piga et al. 2008), IL-6 (usually elevated in type II AIT) (Martino et al. 1986; Bartalena et al. 1994; Martino et al. 2001), IL-13 (Bogazzi et al. 2012) and C-reactive protein (Pearce et al. 2003; Czarnywojtek et al. 2014) are believed to play a helpful role in facilitating the division of AIT type I and II. Moreover, it has been suggested that thyroid autoantibodies, which are found in the serum of some of patients undergoing AM therapy (Foresti et al. 1985; Monteiro et al. 1986; Martino et al. 2001), can be used to make this distinction: TSHR-Abs are thought to be associated with type I AIT, while TPO-Abs and Tg-Abs are thought to play a role in type II AIT. Therefore, in this study we examined the changes of the autoantibody titers in patients with AIT in an attempt to explore what role they have in the pathogenesis of amiodarone-induced thyroid dysfunction. Based on our results, we were not able to make a distinction between the two different types of AIT.

**MATERIALS AND METHODS**

The study consisted of 280 patients that were diagnosed in the Department of Endocrinology, Metabolism and Internal Medicine (217 patients) in Poznan, and in the Department of Nuclear Medicine (63 patients) in Warsaw, Poland between January 2003 and December 2014. TPO-Abs, Tg-Abs, TSHR-Abs were analyzed retrospectively, and compared in euthyroid, hyperthyroid (AIT), and hypothyroid (AIH) patients. Additionally, TSH and thyroid hormones (TH) were examined.

**Patients**

Initially, a retrospective analysis of the medical records was performed. There were 280 patients (225 males and 55 females, with a male: female ratio of 9.7:1) with ages ranging from 36 to 92 years (median age 67). The patients were divided into four groups:

- **Group A:** Euthyroid patients with a history of hyperthyroidism prior to the administration of AM (patients planned to have reintroduced AM as a life-saving drug)
- **Group B:** Hyperthyroid patients (AIT) with normal radioiodine uptake [RAIU (+)], a half-year after discontinuation of AM.
- **Group C:** Hyperthyroid patients (AIT) with extremely reduced radioiodine uptake [RAIU (–)], chronically taking AM.
- **Group D:** Hypothyroid patients who had AM withdrawn after about 3 months of the therapy.
The study design and procedures were approved by the Poznan University of Medical Sciences Medical Ethics Committee. All participants provided written consent.

**Diagnosis of AIT and AIH**

AIT was defined by the following criteria: increased fT4, fT3, and suppressed TSH levels that occurred during therapy or within two years after the AM withdrawal, and a negative titer of circulating thyroid auto-antibodies (Tg-Ab, TPO-Ab, TSHR-Abs) (Han et al. 2009). AIH was defined by low levels of T3 or free T3, by age, and by an elevated TSH level after AM therapy (Connolly 1999).

**Assays**

Hormonal assessment of serum TSH (normal range: 0.27–4.2 μIU/mL), free thyroxine (fT4, normal range: 11.5–21.5 pmol/L) and triiodothyronine (fT3, norm range: 3.9–6.8 pmol/L) was performed using a Hitachi Cobas e601 chemiluminescent analyzer (Roche Diagnostics, Basel, Switzerland). The TSH concentration was measured with a third-generation assay (sensitivity: 0.005 μIU/mL). The concentration of autoantibodies was assessed by the radioimmunological method using second-generation antibodies (RIA-2 Dynotest TRAK human, BRAHMS Diagnostic GmbH, Berlin, Germany). Normal ranges were defined according to the laboratory and kits they used. The ranges were as follows: TSHR-Abs <2 IU/L, Tg-Abs <115 IU/mL, TPO-Abs <35 IU/mL, free T4: 11.5–21.5 pmol/L, free T3: 3.9–6.8 pmol/L, and TSH: 0.27–4.2 μIU/mL.

**Statistical analysis**

The collected data were analyzed using the Statistica 10 from StatSoft (SSS), version 10.0 (Krakow, Poland). Descriptive data were presented as mean and standard deviation (SD). Due to the normal distribution, differences between quantitative data were evaluated by using ANOVA (Kruskal-Wallis test). In order to verify differences that existed amongst groups, a multiple comparisons Dunn test was performed. A p-value below 0.05 was considered statistically significant.

**RESULTS**

In group A (mean age: 50±19 years) the average dose of AM previously administered was from 150 to 900 mg/day. The median time of the withdrawal of the drug ranged from ½ to 3 years. In this group, AM was to be reintroduced in the case of life-threatening tachyarrhythmias. In group B (mean age: 71.5±11.9 years), the time of discontinuation of AM ranged from 6 to 27 months (median 11.2 months). The patients from this group were classified as having type I AIT due to RAIU (+). Patients from group C (mean age: 64.2±13.1 years, chronically taking AM), with RAIU (–), were classified to type II AIT. The daily dose of AM was 200 mg and the median time of therapy was 37 months (from 5 to 76 months). In group D – patients with AIH – (mean age: 65.1±16.6 years), the median time of the AM discontinuation was 17.5 months, ranging from 4 to 37 months.

Serum TSH, fT4 and fT3 concentrations are presented in Table 1. The highest concentrations of fT4 (32.3±8.0 pmol/L) and fT3 (12.1±11.5 pmol/L) were found in AIT patients with extremely reduced RAIU (–) chronically taking AM (group C). The lowest fT4 (10.5±1.9 pmol/L) and fT3 (3.7±0.6 pmol/L) were observed in hypothyroid patients (group D). The level of TSH was the lowest in group C (0.03±0.04 μIU/mL) and extremely high in the case of group D (9.2±3.9 μIU/mL).

There were no significant differences regarding measured TSH, fT4 and fT3 in hyperthyroid groups B and C. The titers of serum TSHR-Abs were not elevated in any of the studied groups. The mean values were: 0.5±0.2 (group A), 0.7±0.5 (group B), 1.0±0.7 (group C), and 0.4±0.3 IU/L (group D). We found statistically sig-
significant differences between groups: A and C ($p=0.001$), B and C ($p=0.02$), B and D ($p=0.04$), C and D ($p=0.02$). Further details of these results are shown in Figure 1.

The titers of Tg-Abs were within the normal range or decreased in most cases. The levels of the mean serum Tg-Abs were 58.7±36.8, 40.7±26.9, 48.6±27.3 and 20.8±8.3 IU/ml, in groups A–D respectively. We found statistically significant differences between groups A and B ($p=0.001$), A and D ($p<0.0001$), B and D ($p=0.003$), C and D ($p<0.0001$). Results are shown in Figure 2.

In most cases, serum TPO-Abs titers were not elevated in any of the studied groups. The mean serum values of TPO-Abs were: 27.6±11.5 (group A), 25.0±14.3 (group B), 28.4±13.3 (group C), and 23.2±12.4 IU/mL (group D). The changes did not differ (Kruskal-Wallis test) between examined patients. Results are shown in Figure 3.

**DISCUSSION**

Thyroid autoantibodies (TPO-Abs, Tg-Abs, TSHR-Abs) play a crucial role in the development and differentiation of Hashimoto’s and Graves’ Diseases. For example, it is likely that autoimmunity against TSHR is what initiates the immune response in Graves’ ophthalmopathy (Wiersinga 2011). On the other hand, the role of autoimmunity and the significance of antithyroid autoantibodies in the pathogenesis of amiodarone-induced thyroid dysfunction (AIT and AIH), in patients without pre-existent thyroid diseases, are still unclear. It is highly probable that the abnormal activation of T lymphocytes contributes to the destruction of thyroid tissue caused by TPO-Abs and Tg-Abs (Foresti et al. 1985; Martino et al. 1986).

In this study we tried to identify changes in TPO-Abs, Tg-Abs, and TSHR-Abs titers in all patients that were observed. Out of the 280 studied patients, in 258 patients with AIT (groups A, B, and C) and 22 with AIH (group D), the serum titers of thyroid Abs were not elevated – for the most part they fell in the normal range. Even though we found statistically significant differences in TSHR-Abs and Tg-Abs titers, they had no clinical implications because most titer values were in the normal range.

The fact that antibody titers in AIT and AIH were shown to be negative in our pilot study is significant because the existing literature on the topic is relatively scarce. Our data suggests that antithyroid Abs are of relatively minor importance in patients on AM therapy – both during the AM treatment and after its withdrawal. This begs the question: to what degree are autoantibodies instrumental in the pathogenesis of AIT and AIH? Are they useful in differentiating between type I (a form of Jod Basedow) and type II (destructive thyroiditis) AIT (Bartalena et al. 2004)?

In earlier observations, thyroid autoantibodies were sometimes claimed to be present in type I AIT. According to Martino E et al. (Martino et al. 1986), circulating thyroid Abs could be found in all AM-induced hyperthyroid patients (particularly in toxic diffuse goiter), while they were rare in toxic multinodular goiter. Monteiro E et al. (Monteiro et al. 1986) observed serum TPO-Abs titer after 30 days of the therapy of AM in 55% of patients. In contrast, levels of Abs were usually absent in AIT type II (Foresti et al. 1985; Martino et al. 1986). In this way, Abs levels have been used to differentiate between the types of AIT. Our study challenges these observations. It is our opinion that thyroid Abs do not play a role in the distinction of AIT types.

As noted, in our current study, Ab titers in AIT and in AIH were within normal range. This is in contrast to our previous studies of interferon-α-induced hyperthyroidism (IIH), where the antibody titer was...
significantly higher. In terms of interferon-α therapy, we can clearly differentiate two types of hyperthyroidism. Type I is related to Graves’ disease (high titer of TSHR-Abs) and Type II is related to thyroid destruction (Hashitoxicosis), where titers of TSHR-Abs are always in the normal range. Hence, we can conclude that in contrast to AM, INF-α can cause Graves’ disease or Hashitoxicosis, and there is no clinical problem with differentiation into two types (Czarnywojtek et al. 2013). However, in the case of AIT, differentiation is a great challenge even for an experienced endocrinologist or nuclear medicine specialist. In clinical practice most patients have mixed forms of AIT and, according to Han TS (Han et al. 2009) as well as our own observations (Czarnywojtek et al. 2014b), it is often impossible to distinguish type I and type II disease.

**Limitations of the study were as follows:**

The study group was very heterogeneous. On one hand, a large group of patients helped give a more precise estimation of the role of thyroid Abs in the development of AIT. On the other hand the diversity amongst patients studied may confuse the reader.

Statistical calculations of autoantibody titers were made based on a nonparametric test due to normal distribution, because variables of Abs (Tg-Abs, TPO-Abs, and TSH-R Abs) are measured on an interval scale, so the values were presented as mean and SD.

The outcome of our study can be summarized as follows: discontinuation or continuation of AM therapy has no influence on the titer of serum thyroid autoantibodies. The statistically significant differences that were observed were not clinically relevant. The role of autoimmunity and the significance of anti-thyroid autoantibodies in the pathogenesis of amiodarone-induced thyroid dysfunction in patients with pre-existent thyroid diseases remains unclear. Furthermore, we concluded that it is not possible to differentiate between the classifications of AIT (types I and II) based on their antibody titers.

**REFERENCES**


**Thyroid autoantibodies in amiodarone-induced thyrotoxicosis;**

Neuroendocrinology Letters Vol. 36 No. 7 2015 • Article available online: http://node.nel.edu 681